<DOC>
	<DOCNO>NCT02628067</DOCNO>
	<brief_summary>In study , participant multiple type advance ( unresectable and/or metastatic ) solid tumor progress standard care therapy treat pembrolizumab .</brief_summary>
	<brief_title>Study Pembrolizumab ( MK-3475 ) Participants With Advanced Solid Tumors ( MK-3475-158/KEYNOTE-158 )</brief_title>
	<detailed_description />
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Histologically cytologicallydocumented , advance solid tumor one follow type : Anal Carcinoma Biliary Adenocarcinoma ( gallbladder biliary tree ( intrahepatic extrahepatic cholangiocarcinoma ) except Ampulla Vater cancer ) Neuroendocrine Tumors ( well moderatelydifferentiated ) lung , appendix , small intestine , colon , rectum , pancreas Endometrial Carcinoma ( sarcomas mesenchymal tumor exclude ) Cervical Carcinoma Vulvar Carcinoma Small Cell Lung Carcinoma Mesothelioma Thyroid Carcinoma Salivary Gland Carcinoma ( sarcomas mesenchymal tumor exclude ) OR Any advance solid tumor , exception colorectal carcinoma ( CRC ) , Microsatellite Instability ( MSI ) High ( MSIH ) Progression tumor intolerance therapy know provide clinical benefit . There limit number prior treatment regimen Can supply tumor tissue study analysis ( dependent tumor type ) Radiologicallymeasurable disease Performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale Life expectancy least 3 month Adequate organ function Female participant childbearing potential must willing use adequate contraception course study 120 day last dose study medication Male participant partner must childbearing potential must willing use adequate contraception course study 120 day last dose study medication Currently participate receive study therapy participate study investigational agent receive study therapy use investigational device within 4 week first dose study medication Diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study medication Active autoimmune disease require systemic treatment past 2 year Prior anticancer monoclonal antibody ( mAb ) within 4 week prior study Day 1 recover adverse event cause mAbs administer 4 week earlier Prior chemotherapy , target small molecule therapy , radiation therapy within 2 week study Day 1 recover adverse event cause previously administer agent Known additional malignancy within 2 year prior enrollment exception curatively treat basal cell carcinoma skin , squamous cell carcinoma skin and/or curatively resect situ cancer Known active central nervous system ( CNS ) metastases and/or carcinomatous meningitis Has know glioblastoma multiforme brainstem History noninfectious pneumonitis require steroid current pneumonitis Active infection require systemic therapy Known psychiatric substance abuse disorder would interfere cooperation requirement study Pregnant , breastfeeding , expect conceive father child within project duration study , start screen visit 120 day last dose study medication Previously participate pembrolizumab ( MK3475 ) study , receive prior therapy antiprogrammed cell death ( PD ) 1 , antiPDLigand 1 ( antiPDL1 ) , antiPDL2 , immunomodulating mAb drug specifically target Tcell costimulation checkpoint pathway Known history Human Immunodeficiency Virus ( HIV ) Known active Hepatitis B C Received live vaccine within 30 day plan start study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PD-L1</keyword>
	<keyword>MSI</keyword>
	<keyword>microsatellite instability</keyword>
	<keyword>MMR</keyword>
	<keyword>mismatch repair</keyword>
	<keyword>anal carcinoma</keyword>
	<keyword>anal cancer</keyword>
	<keyword>biliary adenocarcinoma</keyword>
	<keyword>biliary cancer</keyword>
	<keyword>cholangiocarcinoma</keyword>
	<keyword>bile duct cancer</keyword>
	<keyword>neuroendocrine tumor</keyword>
	<keyword>carcinoid tumor</keyword>
	<keyword>endometrial carcinoma</keyword>
	<keyword>endometrial cancer</keyword>
	<keyword>cervical carcinoma</keyword>
	<keyword>cervical cancer</keyword>
	<keyword>vulvar carcinoma</keyword>
	<keyword>vulvar cancer</keyword>
	<keyword>small cell lung carcinoma</keyword>
	<keyword>small cell lung cancer</keyword>
	<keyword>SCLC</keyword>
	<keyword>mesothelioma</keyword>
	<keyword>thyroid carcinoma</keyword>
	<keyword>thyroid cancer</keyword>
	<keyword>salivary gland carcinoma</keyword>
	<keyword>salivary gland cancer</keyword>
	<keyword>salivary cancer</keyword>
	<keyword>parotid gland cancer</keyword>
	<keyword>advanced solid tumor</keyword>
</DOC>